Double-Blind Method

"Double-Blind Method" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.

Descriptor ID	D004311
MeSH Number(s)	E05.318.780.300 E05.581.500.300 N05.715.360.780.320 N06.850.520.445.300
Concept/Terms	Double-Blind Method Double-Blind Method Double Blind Method Double-Blind Methods Method, Double-Blind Methods, Double-Blind Double-Masked Method Double Masked Method Double-Masked Methods Method, Double-Masked Methods, Double-Masked Double-Masked Study Double Masked Study Double-Masked Studies Studies, Double-Masked Study, Double-Masked Double-Blind Study Double Blind Study Double-Blind Studies Studies, Double-Blind Study, Double-Blind

Below are MeSH descriptors whose meaning is more general than "Double-Blind Method".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Epidemiologic Methods [E05.318]
Epidemiologic Research Design [E05.318.780]
Double-Blind Method [E05.318.780.300]
Methods [E05.581]
Research Design [E05.581.500]
Double-Blind Method [E05.581.500.300]
Health Care [N]
Health Care Quality, Access, and Evaluation [N05]
Quality of Health Care [N05.715]
Health Care Evaluation Mechanisms [N05.715.360]
Epidemiologic Research Design [N05.715.360.780]
Double-Blind Method [N05.715.360.780.320]
Environment and Public Health [N06]
Public Health [N06.850]
Epidemiologic Methods [N06.850.520]
Epidemiologic Research Design [N06.850.520.445]
Double-Blind Method [N06.850.520.445.300]

Below are MeSH descriptors whose meaning is more specific than "Double-Blind Method".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Double-Blind Method" by people in this website by year, and whether "Double-Blind Method" was a major or minor topic of these publications.

Bar chart showing 650 publications over 31 distinct years, with a maximum of 37 publications in 2020

To see the data from this visualization as text, click here.

Year	Minor Topic	Total
1996	10	10
1997	9	9
1998	12	12
1999	11	11
2000	8	8
2001	10	10
2002	11	11
2003	17	17
2004	21	21
2005	31	31
2006	24	24
2007	18	18
2008	24	24
2009	26	26
2010	20	20
2011	21	21
2012	30	30
2013	34	34
2014	29	29
2015	22	22
2016	23	23
2017	29	29
2018	28	28
2019	29	29
2020	37	37
2021	26	26
2022	24	24
2023	14	14
2024	30	30
2025	21	21
2026	1	1

Below are the most recent publications written about "Double-Blind Method" by people in Profiles.

Deane KD, Striebich CC, Feser ML, O'Dell JR, James JA, Sparks JA, Davis JM, Graf J, McMahon MA, Solow EB, Forbess LJ, Tiliakos A, Schiopu E, Danila MI, Horowitz DL, Kay J, Strickland CD, Guthridge JM, Arriens C, Grossman JM, Kristen Demoruelle M, Bemis EA, Frazer-Abel A, Fleischer CL, Fox DA, Mikuls TR, Greenleaf M, York K, Walker S, Keyes-Elstein L, Byron M, Fedler J, Goldmuntz EA, Holers VM. A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis. Arthritis Rheumatol. 2026 Apr; 78(4):809-820.

View in: PubMed
Marzo-Ortega H, Navarro-Compan V, Dubreuil M, Mease PJ, Magrey M, Rudwaleit M, D'Agostino MA, Gaffney K, Kay J, de la Loge C, Massow U, Taieb V, Vaux T, Deodhar A. Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies. RMD Open. 2025 11 28; 11(4).

View in: PubMed
Wang X, Pabon MA, Makuvire TT, Maimaiti R, Abraham TP, Barriales-Villa R, Claggett BL, Coats CJ, Maron MS, Masri A, Meder B, Nassif ME, Olivotto I, Owens AT, Saberi S, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Solomon SD, Hegde SM. Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM. Circ Heart Fail. 2026 Jan; 19(1):e013918.

View in: PubMed
Lebwohl M, Gooderham MJ, Warren RB, Tha?i D, Foley P, Gottlieb AB, Torres T, Popmihajlov Z, Jou YM, Linaberry M, Daamen C, Griffiths CEM. Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis. Clin Exp Dermatol. 2025 Sep 25; 50(10):2030-2036.

View in: PubMed
Sullivan-B?lyai JZ, Allen LB, Cannon R, Cohane KP, Dunzo E, Goldwater R, StCyr K, Wang Y, Klempner MS. A Phase 1 Study in Healthy Subjects to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (S315) Against Diphtheria Toxin. J Infect Dis. 2025 Sep 15; 232(3):534-539.

View in: PubMed
Garcia-Pavia P, Maron MS, Masri A, Merkely B, Nassif ME, Pe?a-Pe?a ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, Correia EB, Dybro AM, Elliott P, Hegde SM, Lakdawala NK, Lewis GD, Mann A, Miao ZM, Nair A, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025 Sep 11; 393(10):949-960.

View in: PubMed
Randall L, Xiang Y, Matsumoto T, Giannarelli D, Milla DP, Lopez KA, Acevedo A, Vizkeleti J, Salani R, Nogueira-Rodrigues A, Mejia FC, Korach J, Akilli H, Lee JY, Saevets VV, Samouelian V, Sehouli J, Tharavichikul E, Sukhin V, Colombo N, Chang CL, Cueva JF, Lalondrelle S, Petru E, Szamreta E, Nguyen AM, Yamada K, Li K, Pignata S, Lorusso D. Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer. Gynecol Oncol. 2025 Aug; 199:88-95.

View in: PubMed
Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS, Clerisme-Beaty E, Coeck C, Gu H, Ritter I, Schlosser A, Stowasser S, Voss F, Weimann G, Zoz DF, Martinez FJ. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2203-2214.

View in: PubMed
Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2193-2202.

View in: PubMed
Butterfield NN, Luzon Rosenblut C, Fava M, Correll CU, Rothschild AJ, Murrough JW, Mathew SJ, Beatch GN, Grayson C, Harden C, Qian J, McIntosh J, Namdari R, Kenney C. Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2025 05 01; 8(5):e2514278.

View in: PubMed

People

Explore

Similar Concepts

Top Journals